ONE GIANT LEAP FOR MAN’S BEST FRIEND

INTRODUCING GALLIPRANT® (grapiprant tablets)

TREAT OSTEOARTHRITIS (OA) WHEN DOGS NEED IT

One key to your canine patients’ health is helping them stay active. Start targeted pain relief from the earliest diagnosed stages of canine OA with Galliprant. Give these dogs the relief they need and help keep them doing the things they love.

TREAT WITH GALLIPRANT FROM THE EARLIEST DIAGNOSED STAGES OF CANINE OA

- Galliprant is a pigrant class drug for a new class of canine OA therapy
- Mode of action targets canine OA pain and inflammation while reducing the impact on GI, kidney and liver homeostasis
- Proven safe
- Most dogs can be dosed with a whole or half tablet

GALLIPRANT PRICING

<table>
<thead>
<tr>
<th>Size (mg)</th>
<th>Tablets per bottle</th>
<th>Price per bottle</th>
</tr>
</thead>
<tbody>
<tr>
<td>20 mg</td>
<td>30</td>
<td>$24.00</td>
</tr>
<tr>
<td>60 mg</td>
<td>30</td>
<td>$48.30</td>
</tr>
<tr>
<td>100 mg</td>
<td>30</td>
<td>$72.60</td>
</tr>
<tr>
<td>20 mg</td>
<td>90</td>
<td>$72.00</td>
</tr>
<tr>
<td>60 mg</td>
<td>90</td>
<td>$144.90</td>
</tr>
<tr>
<td>100 mg</td>
<td>90</td>
<td>$217.80</td>
</tr>
</tbody>
</table>

CONTACT YOUR ELANCO, ARATANA OR DISTRIBUTOR REPRESENTATIVE TO INCORPORATE GALLIPRANT INTO YOUR CANINE OA PAIN PROTOCOL TODAY

To learn more, please visit galliprantfordogs.com/vet

Galliprant is indicated for the control of pain and inflammation associated with osteoarthritis in dogs.

IMPORTANT SAFETY INFORMATION

Not for use in humans. For use in dogs only. Keep this and all medications out of reach of children and pets. Store out of reach of dogs and other pets in a secured location in order to prevent accidental ingestion or overdose. Do not use in dogs that have a hypersensitivity to grapiprant. If Galliprant is used long term, appropriate monitoring is recommended. Concomitant use of Galliprant with other anti-inflammatory drugs, such as COX-inhibiting NSAIDs or corticosteroids, should be avoided. Concurrent use with other anti-inflammatory drugs or protein-bound drugs has not been studied. The safe use of Galliprant has not been evaluated in dogs younger than 9 months of age and less than 8 lbs (3.6 kg), dogs used for breeding, pregnant or lactating dogs, or dogs with cardiac disease. The most common adverse reactions were vomiting, diarrhea, decreased appetite, and lethargy. Please see enclosed product label or call 1-888-545-5973 for full prescribing information.

GALLIPRANT® (grapiprant tablets)

For oral use in dogs only

20 mg, 60 mg and 100 mg flavored tablets

A prostaglandin E2 (PGE2) EP4 receptor antagonist; non-cyclooxygenase inhibiting, non-steroidal anti-inflammatory drug

Caution: The use of excessive tablets is not recommended; toxicity in dogs has not been studied. Concomitant use with other anti-inflammatory drugs, such as COX-inhibiting non-steroidal anti-inflammatory drugs (NSAIDs), should be avoided. If additional pain medication is needed after a daily dose of GALLIPRANT, non-NSAID/non-cyclooxygenase class of analgesics may be used.

The concomitant use of protein-bound drugs with GALLIPRANT has not been studied. Concomitant use of protein-bound drugs include corticosteroids, anticonvulsants and behavioral medications.

Drug compatibility should be monitored in patients requiring adjuvant therapy. Concomitant use of cephalosporins when using GALLIPRANT may increase the risk of hemolytic anemia.

The use of GALLIPRANT® in dogs with cardiac disease has not been studied. It is not known whether dogs with a history of hypercholesterolemia to hyperlipidemia will exhibit hyperglycemia to hyperlipidemia.

Adverse reactions in dogs receiving GALLIPRANT may include vomiting, diarrhea, anorexia, inappetence, lethargy, and acute renal failure.

The structural formula is:

\[
\text{CH}_3
\]

\[
\text{O}
\]

\[
\text{O}
\]

\[
\text{CH}_3
\]

H

S

O

H

H

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]

\[
\text{CH}_3\]